Ifenprodil Improves Long-Term Neurologic Deficits Through Antagonizing Glutamate-Induced Excitotoxicity After Experimental Subarachnoid Hemorrhage

2021 ◽  
Author(s):  
Jing-yi Sun ◽  
Shi-jun Zhao ◽  
Hong-bin Wang ◽  
Ya-jun Hou ◽  
Qiong-jie Mi ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Neurologic Deficits ◽  
Experimental Subarachnoid Hemorrhage

Negative Allosteric Modulator of mGluR1 Improves Long-Term Neurologic Deficits after Experimental Subarachnoid Hemorrhage

2020 ◽  
Vol 11 (18) ◽  
pp. 2869-2880
Author(s):  
Hong-Bin Wang ◽  
Wei-qi Wang ◽  
Qing-Jian Wu ◽  
Ya-jun Hou ◽  
Han-xia Li ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Allosteric Modulator ◽  
Neurologic Deficits ◽  
Experimental Subarachnoid Hemorrhage ◽  
Negative Allosteric Modulator

Early Transient Mild Hypothermia Attenuates Neurologic Deficits and Brain Damage After Experimental Subarachnoid Hemorrhage in Rats

2018 ◽  
Vol 109 ◽  
pp. e88-e98 ◽  
Author(s):  
Nadine Lilla ◽  
Christoph Rinne ◽  
Judith Weiland ◽  
Thomas Linsenmann ◽  
Ralf-Ingo Ernestus ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Brain Damage ◽  
Mild Hypothermia ◽  
Neurologic Deficits ◽  
Experimental Subarachnoid Hemorrhage

Long-term cognitive dysfunction following experimental subarachnoid hemorrhage: New perspectives

2008 ◽  
Vol 213 (2) ◽  
pp. 336-344 ◽  
Author(s):  
Ken Takata ◽  
Huaxin Sheng ◽  
Cecil O. Borel ◽  
Daniel T. Laskowitz ◽  
David S. Warner ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Cognitive Dysfunction ◽  
Experimental Subarachnoid Hemorrhage

Loss of long-term potentiation in the hippocampus after experimental subarachnoid hemorrhage in rats

Neuroscience ◽  
2010 ◽  
Vol 165 (2) ◽  
pp. 418-426 ◽  
Author(s):  
A. Tariq ◽  
J. Ai ◽  
G. Chen ◽  
M. Sabri ◽  
H. Jeon ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Long Term Potentiation ◽  
Term Potentiation ◽  
Experimental Subarachnoid Hemorrhage

scholarly journals Long-term impairment of neurovascular coupling following experimental subarachnoid hemorrhage

2019 ◽  
Vol 40 (6) ◽  
pp. 1193-1202 ◽  
Author(s):  
Matilde Balbi ◽  
Max Jativa Vega ◽  
Athanasios Lourbopoulos ◽  
Nicole A Terpolilli ◽  
Nikolaus Plesnila
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Delayed Cerebral Ischemia ◽  
Neurovascular Coupling ◽  
Early Brain Injury ◽  
Vessel Diameter ◽  
Two Photon Microscopy ◽  
Two Photon ◽  
Experimental Subarachnoid Hemorrhage

CO2-reactivity and neurovascular coupling are sequentially lost within the first 24 h after subarachnoid hemorrhage (SAH). Whether and when these impairments recover is not known. Therefore, we investigated the reactivity of pial and intraparenchymal vessels by in vivo two-photon microscopy one month after experimental SAH. C57BL/6 mice were subjected to either sham surgery or SAH by filament perforation. One month later, cerebral blood flow following CO2-challenge and forepaw stimulation was assessed by laser Doppler fluxmetry. Diameters of pial and intraparenchymal arterioles were quantified by in vivo two-photon microscopy. One month after SAH, pial and parenchymal vessels dilated in response to CO2. Neurovascular coupling was almost completely absent after SAH: vessel diameter did not change upon forepaw stimulation compared to a 20% increase in sham-operated mice. The current results demonstrate that neurovascular function differentially recovers after SAH: while CO2-reactivity normalizes within one month after SAH, neurovascular coupling is still absent. These findings show an acute and persistent loss of neurovascular coupling after SAH that may serve as a link between early brain injury and delayed cerebral ischemia, two distinct pathophysiological phenomena after SAH that were so far believed not to be directly related.

scholarly journals Parenteral artemisinins are associated with reduced mortality and neurologic deficits and improved long-term behavioral outcomes in children with severe malaria

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Andrea L. Conroy ◽  
Robert O. Opoka ◽  
Paul Bangirana ◽  
Ruth Namazzi ◽  
Allen E. Okullo ◽  
...  
Keyword(s):  
Executive Function ◽  
Hospital Mortality ◽  
Cerebral Malaria ◽  
Severe Malaria ◽  
Behavioral Outcomes ◽  
Artemisinin Derivatives ◽  
Neurologic Deficits ◽  
Adjusted Scores

Abstract Background In 2011, the World Health Organization recommended injectable artesunate as the first-line therapy for severe malaria (SM) due to its superiority in reducing mortality compared to quinine. There are limited data on long-term clinical and neurobehavioral outcomes after artemisinin use for treatment of SM. Methods From 2008 to 2013, 502 Ugandan children with two common forms of SM, cerebral malaria and severe malarial anemia, were enrolled in a prospective observational study assessing long-term neurobehavioral and cognitive outcomes following SM. Children were evaluated a week after hospital discharge, and 6, 12, and 24 months of follow-up, and returned to hospital for any illness. In this study, we evaluated the impact of artemisinin derivatives on survival, post-discharge hospital readmission or death, and neurocognitive and behavioral outcomes over 2 years of follow-up. Results 346 children received quinine and 156 received parenteral artemisinin therapy (artemether or artesunate). After adjustment for disease severity, artemisinin derivatives were associated with a 78% reduction in in-hospital mortality (adjusted odds ratio, 0.22; 95% CI, 0.07–0.67). Among cerebral malaria survivors, children treated with artemisinin derivatives also had reduced neurologic deficits at discharge (quinine, 41.7%; artemisinin derivatives, 23.7%, p=0.007). Over a 2-year follow-up, artemisinin derivatives as compared to quinine were associated with better adjusted scores (negative scores better) in internalizing behavior and executive function in children irrespective of the age at severe malaria episode. After adjusting for multiple comparisons, artemisinin derivatives were associated with better adjusted scores in behavior and executive function in children <6 years of age at severe malaria exposure following adjustment for child age, sex, socioeconomic status, enrichment in the home environment, and the incidence of hospitalizations over follow-up. Children receiving artesunate had the greatest reduction in mortality and benefit in behavioral outcomes and had reduced inflammation at 1-month follow-up compared to children treated with quinine. Conclusions Treatment of severe malaria with artemisinin derivatives, particularly artesunate, results in reduced in-hospital mortality and neurologic deficits in children of all ages, reduced inflammation following recovery, and better long-term behavioral outcomes. These findings suggest artesunate has long-term beneficial effects in children surviving severe malaria.

Sign in / Sign up

Export Citation Format

Share Document